Given the limited efficacy of CPI alone for microsatellite stable cancers with ORR ranging from 0-7% (48–50), these promising findings suggest that dual blockade of SIRPα and PD-1 may augment phagocytosis and play a role in overcoming CPI resistance. Here, SIRPA is linked to cancer.